Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
21 May 2024
|
N 00:12 | Elacestrant 2 changes history +3,173 [Rithish Nimmagadda (2×)] | |||
|
00:12 (cur | prev) +313 Rithish Nimmagadda talk contribs | ||||
N |
|
00:09 (cur | prev) +2,860 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=elacestrant |aOrAn=an |drugClass=estrogen receptor antagonist |indicationType=treatment |indication=estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer that has progressed following ≥1 line of endocrine-based therapy in postmenopausal women or adult men. |fdaLIADAdult=Dosage of elacestrant hydro...") |
00:10 | User:Rithish Nimmagadda diffhist +17 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) |
20 May 2024
|
23:07 | User:Rithish Nimmagadda 3 changes history +62 [Rithish Nimmagadda (3×)] | |||
|
23:07 (cur | prev) +25 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
20:32 (cur | prev) +23 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
20:18 (cur | prev) +14 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) |
N 23:07 | Velmanase alfa-tycv diffhist +7,709 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=velmanase alfa-tycv |aOrAn=an |drugClass=recombinant preparation of human lysosomal alpha-mannosidase |indicationType=treatment |indication=non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients |adverseReactions=Most common adverse reactions (incidence >20%) are hypersensitivity reactions (including anaphylaxis), nasopharyngitis, pyrexia, headache, and arthralgia. |blac...") |
|
N 20:36 | Retifanlimab-dlwr 3 changes history +8,754 [Rithish Nimmagadda (3×)] | |||
|
20:36 (cur | prev) −296 Rithish Nimmagadda talk contribs | ||||
|
20:33 (cur | prev) +86 Rithish Nimmagadda talk contribs | ||||
N |
|
20:31 (cur | prev) +8,964 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=retifanlimab-dlwr |aOrAn=an |indicationType=treatment |indication=adults with metastatic or recurrent locally advanced Merkel cell carcinoma . Indication approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. |adverseReactions=Adverse effects (≥10%): fatigue...") |
N 20:18 | Tofersen diffhist +3,936 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=tofersen |aOrAn=an |drugClass=antisense oligonucleotide |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |adverseReactions=he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia. |fdaLIADAdult=...") |
|
03:56 | Leniolisib 2 changes history +3,116 [Alen Antony (2×)] | |||
|
03:56 (cur | prev) +1,712 Alen Antony talk contribs | ||||
|
03:38 (cur | prev) +1,404 Alen Antony talk contribs |
19 May 2024
21:29 | Industrial and organizational psychology diffhist +282 Badgettrg talk contribs (→Engagement) |
03:54 | Chronic obstructive pulmonary disease history and symptoms diffhist +1,728 Kosar Doraghi talk contribs |
18 May 2024
16:02 | User:Rithish Nimmagadda diffhist +18 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) |
|
N 16:02 | Ritlecitinib 2 changes history +10,128 [Rithish Nimmagadda (2×)] | |||
|
16:02 (cur | prev) +22 Rithish Nimmagadda talk contribs | ||||
N |
|
16:01 (cur | prev) +10,106 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=ritlecitinib |aOrAn=a |drugClass=janus kinase 3 (JAK3) inhibitor and also an inhibitor of the tyrosine kinase |indicationType=treatment |indication=severe alopecia areata in adults and adolescents 12 years of age and older |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, i...") |
|
00:29 | User:Archana.vajjala 2 changes history 0 [Archana.vajjala (2×)] | |||
|
00:29 (cur | prev) −6 Archana.vajjala talk contribs (→Dr Archana Yadav Vajjala) Tags: Manual revert Visual edit | ||||
|
00:23 (cur | prev) +6 Archana.vajjala talk contribs Tags: Manual revert Visual edit |
17 May 2024
|
23:29 | User:Archana.vajjala 5 changes history +2 [Archana.vajjala (5×)] | |||
|
23:29 (cur | prev) −6 Archana.vajjala talk contribs (→Dr Archana Yadav Vajjala) Tag: Visual edit | ||||
|
23:29 (cur | prev) +24 Archana.vajjala talk contribs (→Work Experience) Tag: Visual edit | ||||
|
09:46 (cur | prev) +3 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
09:36 (cur | prev) +6 Archana.vajjala talk contribs (→Archana Vajjala) Tag: Visual edit | ||||
|
06:28 (cur | prev) −25 Archana.vajjala talk contribs (→Work Experience) Tag: Visual edit |
|
20:01 | Leniolisib 4 changes history +3,011 [Alen Antony (4×)] | |||
|
20:01 (cur | prev) +305 Alen Antony talk contribs | ||||
|
19:37 (cur | prev) +3 Alen Antony talk contribs | ||||
|
19:36 (cur | prev) +1,179 Alen Antony talk contribs | ||||
|
18:56 (cur | prev) +1,524 Alen Antony talk contribs |
|
17:21 | User:Rithish Nimmagadda 3 changes history +49 [Rithish Nimmagadda (3×)] | |||
|
17:21 (cur | prev) +17 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
16:58 (cur | prev) +15 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
15:40 (cur | prev) +17 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) |
N 17:21 | Quizartinib diffhist +8,825 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=quizartinib |aOrAn=a |drugClass=a kinase inhibitor |indicationType=treatment |indication=adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. |hasBlackBoxWarning=Yes |adverseReactions=The most common (>20%) adverse reactions, including laboratory abnormalities, are decreased lymphocytes, decreased potassium,...") |
N 16:40 | Lotilaner diffhist +2,182 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=lotilaner |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor |indication=ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis |adverseReactions=The most common adverse reaction was instillation site stinging and burning |fdaLIADAdult=still one drop of lotilaner in each eye twice daily (approximately 12 hours apart) for 6 weeks. |fdaLIADPed=Safety...") |
15:38 | Bimekizumab diffhist +7,057 Rithish Nimmagadda talk contribs |
16 May 2024
|
N 14:41 | Leniolisib 3 changes history +359 [Alen Antony (3×)] | |||
|
14:41 (cur | prev) +2 Alen Antony talk contribs | ||||
|
14:40 (cur | prev) −2 Alen Antony talk contribs | ||||
N |
|
14:40 (cur | prev) +359 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=leniolisib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. |adverseReactions=headache, sinusitis, and {{atopic dermatitis}}. |brandNames=JOENJA }}") |
|
14:34 | Trofinetide 6 changes history +5,945 [Alen Antony (6×)] | |||
|
14:34 (cur | prev) +1,803 Alen Antony talk contribs | ||||
|
14:19 (cur | prev) −1 Alen Antony talk contribs Tag: Manual revert | ||||
|
03:47 (cur | prev) +1 Alen Antony talk contribs | ||||
|
03:46 (cur | prev) +2,158 Alen Antony talk contribs | ||||
|
03:29 (cur | prev) +912 Alen Antony talk contribs | ||||
|
03:09 (cur | prev) +1,072 Alen Antony talk contribs |
|
N 10:15 | Avacincaptad pegol 2 changes history +3,387 [Muhammad Waleed (2×)] | |||
|
10:15 (cur | prev) +132 Muhammad Waleed talk contribs | ||||
N |
|
10:11 (cur | prev) +3,255 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=Avacincaptad Pegol |drugClass=Avacincaptad pegol is a complement C5 protein inhibitor |indication=IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |adverseReactions=Common adverse reactions (≥5% of patients) include conjunctival hemorrhage, increased intraocular pressure, and endophthalmitis. |blackBoxWarningTitle=There is no black box warning listed for IZERV...") |
|
10:14 | Talquetamab-tgvs 2 changes history +2,312 [Muhammad Waleed (2×)] | |||
|
10:14 (cur | prev) +505 Muhammad Waleed talk contribs | ||||
|
09:28 (cur | prev) +1,807 Muhammad Waleed talk contribs |
09:31 | Upload log Muhammad Waleed talk contribs uploaded File:Talvey (talquetamab-tgvs).png (image for the drug Talvey) |
|
07:07 | User:AED 4 changes history +102 [Alara E. Dagsali (4×)] | |||
|
07:07 (cur | prev) +21 Alara E. Dagsali talk contribs | ||||
|
06:42 (cur | prev) +24 Alara E. Dagsali talk contribs | ||||
|
06:33 (cur | prev) +27 Alara E. Dagsali talk contribs | ||||
|
06:22 (cur | prev) +30 Alara E. Dagsali talk contribs |
|
N 07:06 | Diclofenac Patch 2 changes history +48,613 [Alara E. Dagsali (2×)] | |||
|
07:06 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
N |
|
07:06 (cur | prev) +48,610 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr...") |
|
N 06:42 | Cortisone Acetate 2 changes history +14,098 [Alara E. Dagsali (2×)] | |||
|
06:42 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
N |
|
06:42 (cur | prev) +14,095 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen...") |
|
N 06:33 | Clocortolone Pivalate 2 changes history +4,446 [Alara E. Dagsali (2×)] | |||
|
06:33 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
N |
|
06:32 (cur | prev) +4,443 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed...") |
|
N 06:21 | Scorpion 2 changes history +12,448 [Alara E. Dagsali (2×)] | |||
|
06:21 (cur | prev) +30 Alara E. Dagsali talk contribs | ||||
N |
|
06:20 (cur | prev) +12,418 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u...") |
15 May 2024
|
20:44 | Medication reconciliation 2 changes history +536 [Badgettrg (2×)] | |||
|
20:44 (cur | prev) +1 Badgettrg talk contribs (→Frequency of reconciliation errors) | ||||
|
20:43 (cur | prev) +535 Badgettrg talk contribs |
14:58 | Vamorolone diffhist +11,928 Rafael Garcia talk contribs |
|
14:21 | User:Archana.vajjala 2 changes history −24 [Archana.vajjala (2×)] | |||
|
14:21 (cur | prev) −22 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
12:16 (cur | prev) −2 Archana.vajjala talk contribs Tag: Visual edit |
|
N 10:59 | Lodoxamide 2 changes history +6,537 [Alara E. Dagsali (2×)] | |||
|
10:59 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
N |
|
10:58 (cur | prev) +6,534 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...") |
|
04:40 | Trofinetide 2 changes history +176 [Alen Antony (2×)] | |||
|
04:40 (cur | prev) +41 Alen Antony talk contribs | ||||
|
04:40 (cur | prev) +135 Alen Antony talk contribs |
|
04:28 | Fezolinetant 8 changes history +4,781 [Alen Antony (8×)] | |||
|
04:28 (cur | prev) +1,695 Alen Antony talk contribs | ||||
|
04:21 (cur | prev) +1,499 Alen Antony talk contribs | ||||
|
03:44 (cur | prev) +174 Alen Antony talk contribs | ||||
|
03:37 (cur | prev) +19 Alen Antony talk contribs | ||||
|
02:46 (cur | prev) +589 Alen Antony talk contribs | ||||
|
02:24 (cur | prev) +234 Alen Antony talk contribs | ||||
|
01:32 (cur | prev) +512 Alen Antony talk contribs | ||||
|
01:09 (cur | prev) +59 Alen Antony talk contribs |
14 May 2024
|
21:44 | Fezolinetant 2 changes history +817 [Alen Antony (2×)] | |||
|
21:44 (cur | prev) +723 Alen Antony talk contribs | ||||
|
21:34 (cur | prev) +94 Alen Antony talk contribs |
04:55 | Somatrogon-ghla diffhist +52 Kosar Doraghi talk contribs |
13 May 2024
N 23:48 | Fezolinetant diffhist +84 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}") |
|
N 23:46 | Nirsevimab-alip 2 changes history +5,780 [Alen Antony (2×)] | |||
|
23:46 (cur | prev) +3,844 Alen Antony talk contribs | ||||
N |
|
14:50 (cur | prev) +1,936 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Nirsevimab-alip |aOrAn=a |drugClass=human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody |indicationType=prevention |indication=Respiratory Syncytial Virus (RSV) lower respiratory tract disease for neonates and infants born during or entering their first RSV season and children up to 24 years of age who are vulnerable to severe RSV disease in their second RSV season. |adverseReactions=rashes and injection...") |
N 20:38 | Talquetamab-tgvs diffhist +2,766 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent...") |
14:23 | Non-alcoholic fatty liver disease epidemiology and demographics diffhist +1,197 Badgettrg talk contribs (→Overview) |
12 May 2024
|
23:08 | Vitamin D 2 changes history +1,636 [Badgettrg (2×)] | |||
|
23:08 (cur | prev) +503 Badgettrg talk contribs (→Medical uses) | ||||
|
23:00 (cur | prev) +1,133 Badgettrg talk contribs (→Role in depression prevention) |
21:59 | Systematic review diffhist +3,699 Badgettrg talk contribs (→Living systematic reviews) |
21:06 | Template:KDRG diffhist +47 Kosar Doraghi talk contribs |
|
N 21:04 | Somatrogon-ghla 2 changes history +12,691 [Kosar Doraghi (2×)] | |||
|
21:04 (cur | prev) +215 Kosar Doraghi talk contribs | ||||
N |
|
05:30 (cur | prev) +12,476 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.con] |genericName=somatrogon-ghla |aOrAn=a |drugClass=human growth hormone analog |indicationType=treatment |indication=pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone |hasBlackBoxWarning=Yes |adverseReactions=injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, v...") |
20:52 | Chronic renal failure overview diffhist +13,854 Kosar Doraghi talk contribs |
|
19:35 | (Upload log) [Kosar Doraghi (8×)] | |||
|
19:35 Kosar Doraghi talk contribs uploaded File:IMG 1208.jpeg | ||||
|
19:33 Kosar Doraghi talk contribs uploaded File:IMG 1207.jpeg | ||||
|
19:32 Kosar Doraghi talk contribs uploaded File:IMG 1204.jpeg | ||||
|
19:30 Kosar Doraghi talk contribs uploaded File:IMG 1202.jpeg | ||||
|
19:28 Kosar Doraghi talk contribs uploaded File:IMG 1200.jpeg | ||||
|
19:24 Kosar Doraghi talk contribs uploaded File:IMG 1214.jpeg | ||||
|
05:15 Kosar Doraghi talk contribs uploaded File:IMG 1198.jpeg | ||||
|
05:13 Kosar Doraghi talk contribs uploaded File:IMG 1215.jpeg |
11 May 2024
|
22:32 | Mirikizumab-mrkz 3 changes history +5,248 [Rithish Nimmagadda (3×)] | |||
|
22:32 (cur | prev) +13 Rithish Nimmagadda talk contribs | ||||
|
22:31 (cur | prev) 0 Rithish Nimmagadda talk contribs | ||||
|
22:26 (cur | prev) +5,235 Rithish Nimmagadda talk contribs |
N 20:21 | Elfabrio diffhist +3,351 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio...") |
N 19:36 | Exxua diffhist +44 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}") |
|
19:09 | Facioscapulo-humeral dystrophy 8 changes history +2,898 [Dj (8×)] | |||
|
19:09 (cur | prev) +29 Dj talk contribs (→History) | ||||
|
18:59 (cur | prev) +191 Dj talk contribs | ||||
|
18:45 (cur | prev) +637 Dj talk contribs (→Pathophysiology) | ||||
|
18:41 (cur | prev) +138 Dj talk contribs | ||||
|
17:59 (cur | prev) +789 Dj talk contribs (→Classification) | ||||
|
17:52 (cur | prev) −5 Dj talk contribs | ||||
|
17:51 (cur | prev) +363 Dj talk contribs | ||||
|
17:43 (cur | prev) +756 Dj talk contribs |
12:13 | User:Archana.vajjala diffhist +62 Archana.vajjala talk contribs (→Interests) |
10 May 2024
21:12 | Stress ulcer diffhist +1,682 Badgettrg talk contribs (→Drug classes and options available) |
|
19:11 | Sotagliflozin 5 changes history +3,623 [Alen Antony (5×)] | |||
|
19:11 (cur | prev) +829 Alen Antony talk contribs | ||||
|
18:12 (cur | prev) +833 Alen Antony talk contribs | ||||
|
17:54 (cur | prev) +545 Alen Antony talk contribs | ||||
|
17:46 (cur | prev) +744 Alen Antony talk contribs | ||||
|
17:12 (cur | prev) +672 Alen Antony talk contribs |
04:13 | Electronic medical record diffhist +119 Badgettrg talk contribs (→Problem lists) |
01:58 | User:Archana.vajjala diffhist +2 Archana.vajjala talk contribs |
9 May 2024
|
N 23:59 | Sotagliflozin 3 changes history +1,667 [Alen Antony (3×)] | |||
|
23:59 (cur | prev) +19 Alen Antony talk contribs | ||||
|
15:17 (cur | prev) +1,230 Alen Antony talk contribs | ||||
N |
|
04:57 (cur | prev) +418 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=sotagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=prophylaxis |indication=heart failure in patients with risk of heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |adverseReactions=urinary tract infection, volume depletion, diarrhea, and hypoglycemia. }}") |
14:35 | User:Rithish Nimmagadda diffhist +123 Rithish Nimmagadda talk contribs (→Education) |
|
N 14:32 | Epcoritamab-bysp 3 changes history +11,459 [Rithish Nimmagadda (3×)] | |||
|
14:32 (cur | prev) +11,409 Rithish Nimmagadda talk contribs | ||||
|
13:14 (cur | prev) +4 Rithish Nimmagadda talk contribs | ||||
N |
|
13:10 (cur | prev) +46 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=VSRN }}") |
|
N 10:45 | FUTIBATINIB 2 changes history +1,225 [Hafiza Amna Qadeer (2×)] | |||
|
10:45 (cur | prev) −12 Hafiza Amna Qadeer talk contribs | ||||
N |
|
10:37 (cur | prev) +1,237 Hafiza Amna Qadeer talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER, MD |OTC=Yes |genericName=FUTIBATINIB |aOrAn=a |drugClass=Kinase Inhibitor |indicationType=treatment |indication=* of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. |adverseReactions=1* Nail Toxicity, stomatitis, dry skin, dry eye, alopecia 2* Musculos...") |
8 May 2024
21:38 | Template:KDRG diffhist +174 Kosar Doraghi talk contribs |
|
N 21:38 | EXXUA 2 changes history +11,572 [Kosar Doraghi (2×)] | |||
|
21:38 (cur | prev) +11 Kosar Doraghi talk contribs | ||||
N |
|
21:32 (cur | prev) +11,561 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Gepirone |aOrAn=a |drugClass=extended-release tablets |indicationType=treatment |indication=major depressive disorder (MDD) in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, nausea, insomnia, abdominal pain, and dyspepsia |blackBoxWarningTitle=WARNING: SUICIDAL THOUGHTS AND BEHAVIORS |blackBoxWarningBody=SEE FULL PRESCRIBING INFORMATION FOR...") |
|
17:11 | Cryptogenic cirrhosis 6 changes history +3,131 [Imam Ali Shah (6×)] | |||
|
17:11 (cur | prev) +8 Imam Ali Shah talk contribs Tag: Visual edit | ||||
|
17:03 (cur | prev) +419 Imam Ali Shah talk contribs (Added CT scan images) Tag: Visual edit | ||||
|
16:45 (cur | prev) +1,626 Imam Ali Shah talk contribs (Added CT scan images) Tag: Visual edit | ||||
|
16:34 (cur | prev) +269 Imam Ali Shah talk contribs Tag: Visual edit | ||||
|
16:26 (cur | prev) +476 Imam Ali Shah talk contribs Tag: Visual edit | ||||
|
16:21 (cur | prev) +333 Imam Ali Shah talk contribs Tag: Visual edit |
16:03 | User:Imam Ali Shah diffhist −61 Imam Ali Shah talk contribs |
N 14:44 | Template:VSRN diffhist +81 Rithish Nimmagadda talk contribs (Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]") |
|
N 14:30 | FRUZAQLA 3 changes history +9,129 [Rithish Nimmagadda (3×)] | |||
|
14:30 (cur | prev) +2 Rithish Nimmagadda talk contribs Tag: Visual edit | ||||
|
14:25 (cur | prev) +35 Rithish Nimmagadda talk contribs | ||||
N |
|
14:10 (cur | prev) +9,092 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma...") |
|
N 14:21 | User:Rithish Nimmagadda 3 changes history +362 [Rithish Nimmagadda (3×)] | |||
|
14:21 (cur | prev) −9 Rithish Nimmagadda talk contribs (→Your Name) | ||||
|
14:21 (cur | prev) +9 Rithish Nimmagadda talk contribs (→Your Name) | ||||
N |
|
14:20 (cur | prev) +362 Rithish Nimmagadda talk contribs (Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India") |
N 13:32 | Fruzaqla diffhist +49 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}") |
|
04:13 | Zuranolone 2 changes history +5,755 [Alen Antony (2×)] | |||
|
04:13 (cur | prev) +2,528 Alen Antony talk contribs | ||||
|
03:48 (cur | prev) +3,227 Alen Antony talk contribs |
01:58 | User:Edzelco diffhist +22 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) |
01:55 | Toripalimab-tpzi diffhist +45,965 Edzelco talk contribs |
7 May 2024
|
N 20:18 | Zuranolone 2 changes history +1,853 [Alen Antony (2×)] | |||
|
20:18 (cur | prev) +1,017 Alen Antony talk contribs | ||||
N |
|
17:27 (cur | prev) +836 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad...") |